- Home
- INZY
INZY
Inozyme Pharma Inc.
as 12-18-2024 1:38pm EST
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 165.1M | IPO Year: | 2020 |
| Target Price: | $16.14 | AVG Volume (30 days): | 885.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.38 - $7.80 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Inozyme Pharma Inc. News
INZY Breaking Stock News: Dive into INZY Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Raymond James Initiates Inozyme Pharma at Outperform With $26 Price Target
GlobeNewswire
21 days ago
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Zacks
a month ago
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
GlobeNewswire
a month ago
Inozyme Pharma to Present at Upcoming Investor Conferences
GlobeNewswire
a month ago
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
MT Newswires
2 months ago
Inozyme Pharma Reports Positive Interim Data From Trial of Potential Kidney Disease Treatment
GlobeNewswire
2 months ago
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
GlobeNewswire
2 months ago
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
Compare INZY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INZY Inozyme Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.